ArticleAnnals of transplantation2025
Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections.
Article in Annals of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Induction immunosuppressive therapy is essential to prevent early acute rejection in kidney transplantation. While basiliximab is typically used in low-immunological-risk patients, low-dose rabbit anti-thymocyte globulin (r-ATG) may offer comparable efficacy with potentially higher infection risk. Evidence comparing both strategies in living-donor transplantation remains limited. MATERIAL AND METHODS This retrospective cohort study included 150 adult patients undergoing their first kidney transplant from living donors at the 108 Military Central Hospital (Vietnam) between January 2022 and January 2025. All recipients were classified as low immunologic risk and received either low-dose r-ATG (4 mg/kg, n=37) or basiliximab (n=113) as induction therapy. Outcomes evaluated included graft and patient survival, biopsy-proven acute rejection (BPAR), renal function (eGFR), and post-transplant infection rates. Multivariable Cox regression was used to identify predictors of rejection. RESULTS The median follow-up duration was 26.65 months. Both groups had 100% patient survival during the follow-up period. Graft failure occurred in 2.7% (r-ATG) and 1.77% (basiliximab) of recipients. BPAR rates were 10.81% and 13.27% in the r-ATG and basiliximab groups, respectively. No significant differences in eGFR or infection rates (CMV, BK virus, bacterial/fungal infections) were observed. HLA mismatch was the only significant predictor of rejection (Class I HR: 3.06; Class II HR: 5.59). CONCLUSIONS In low-risk living-donor kidney transplantation, low-dose r-ATG provides efficacy and safety comparable to basiliximab in terms of graft survival, rejection, and infection rates. These findings support the use of individualized induction strategies, with low-dose r-ATG being a viable alternative to basiliximab in selected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.